General description

A cell-permeable iodo-pyrimidine compound that covalently modifies MIF N-terminal proline and exhibits higher MIF inhibitory potency than ISO-1 (Cat. No. 475837) in cell-free dopachrome tautomerase activity assays (IC₅₀ ~5 vs. 50 µM, respectively, using recombinant human MIF) as well as in cell-based migration assays (50% vs 0% inhibition with respective inhibitor at 10 µM) and anchorage-independent growth (57% vs 0% inhibition with respective inhibitor at 10 µM) using human lung adenocarcinoma A549. Also shown to reduce A549 cellular active Rac1 population (50 µM, 16 h) in vitro and effectively decrease liver tautomerase activity by 50% in mice (1 mg/animal/day or ~50 mg/kg/day via i.p.) in vivo.

A cell-permeable iodo-pyrimidine compound that covalently modifies MIF N-terminal proline and exhibits higher MIF inhibitory potency than ISO-1 (Cat. No. 475837) in cell-free dopachrome tautomerase activity assays (IC₅₀ ~5 vs. 50 µM, respectively, using recombinant human MIF) as well as in cell-based migration assays (50% vs 0% inhibition with respective inhibitor at 10 µM) and anchorage-independent growth (57% vs 0% inhibition with respective inhibitor at 10 µM) using human lung adenocarcinoma A549. Also shown to reduce A549 cellular active Rac1 population (50 µM, 16 h) in vitro and effectively decrease liver tautomerase activity by 50% in mice (1 mg/animal/day or ~50 mg/kg/day via i.p.) in vivo.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Winner, M., et al. 2008. Cancer Res.68, 7253.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Warning

Toxicity: Standard Handling (A)